Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/220710a0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS).
Lupus Sci Med
January 2025
BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Objectives: Systemic lupus erythematosus (SLE) is a disease with heterogeneous treatment patterns largely based on organ involvement and disease severity. The SLE Prospective Observational Cohort Study (SPOCS) collected data worldwide over 3 years from patients with moderate-to-severe SLE. We report real-world patterns of medication use in patients enrolled in SPOCS.
View Article and Find Full Text PDFPneumocystis jirovecii pneumonia increases the 3-months mortality of anti-MDA5-antibody-positive dermatomyositis patients.
Front Immunol
December 2024
Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Background: Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (anti-MDA5+DM) patients are associated with considerable mortality, and opportunistic infections including Pneumocystis jirovecii pneumonia (PJP)is the main cause. This study was to identify clinical characteristics, risk factors, and prognostic factors of PJP diagnosed by bronchoalveolar lavage fluid (BALF) metagenomic next-generation sequencing (mNGS) in anti-MDA5+ DM patients.
Methods: In this retrospective observational study, all patients admitted with suspected pneumonia were detected for mNGS in BALF.
Hydroxychloroquine and Sjögren's disease: current evidences for its use.
Joint Bone Spine
January 2025
Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga No. 15, Col. Belisario Domínguez Sección XVI, CP 14080 Mexico City, Mexico. Electronic address:
About 25-50% of patients with primary Sjögren's disease (SjD) take hydroxychloroquine (HCQ). Although it is widely prescribed, and recommended in international guidelines, its use is mostly based on expert opinion and personal experience. Our aim was to provide a comprehensive overview of the pathogenic mechanisms of HCQ, the current clinical evidence for its use, and its safety in primary SjD.
View Article and Find Full Text PDFMonoclonal antibodies for the management of cutaneous lupus erythematosus: an update on the current treatment landscape.
Clin Exp Dermatol
January 2025
Department of Dermatology, UTHealth McGovern Medical School, Houston, TX, USA.
Article Synopsis
- Cutaneous lupus erythematosus (CLE) is an autoimmune disease that primarily affects the skin, divided into three categories: acute, subacute, and chronic.
- Treatment strategies for CLE involve patient education, medication regimens, and various therapies such as corticosteroids and immunomodulators, but currently, no biologic drugs are specifically approved for CLE.
- Research is ongoing into monoclonal antibodies (mAbs) like belimumab and anifrolumab that have been approved for other lupus conditions, with potential new mAbs being investigated to improve treatment options for CLE patients.
Pro- and anti-inflammatory cytokines mediate the progression of severe anemia in malaria-infected children: A prospective study.
Immun Inflamm Dis
September 2024
Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Ebonyi State University, Abakaliki, Nigeria.
Background: Severe Plasmodium falciparum malarial anemia is still the principal cause of death in children in underdeveloped countries. An imbalance between proinflammatory and anti-inflammatory cytokines is associated with malaria progression. This study evaluated circulating levels of selected inflammatory cytokines among malaria-infected children in Ghana.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!